| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/30/1998 | WO1998017791A1 Production of cartilage tissue using cells isolated from wharton's jelly |
| 04/30/1998 | WO1998017784A1 Method for in vitro preconditioning of myoblasts before transplantation |
| 04/30/1998 | WO1998017779A1 NOVEL FabH |
| 04/30/1998 | WO1998017690A1 Receptor specific brain natriuretic peptide (bnp) |
| 04/30/1998 | WO1998017689A2 Il-12 gene expression and delivery systems and uses |
| 04/30/1998 | WO1998017688A1 Osteometrin related peptides and nucleic acids and diagnosis and therapies using them |
| 04/30/1998 | WO1998017687A2 Secreted proteins and polynucleotides encoding them |
| 04/30/1998 | WO1998017686A1 Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use |
| 04/30/1998 | WO1998017685A1 Novel lanthionine antibiotic compositions and methods |
| 04/30/1998 | WO1998017684A2 Dna sequences encoding fusions of dna repair proteins and uses thereof |
| 04/30/1998 | WO1998017682A1 Serine substituted mutants of bcl-xl/bcl-2 associated cell death regulator |
| 04/30/1998 | WO1998017681A1 Materials and method for the detection and treatment of wegener'sgranulomatosis |
| 04/30/1998 | WO1998017680A1 Peptide analogues containing a 7-membered lactam ring |
| 04/30/1998 | WO1998017679A1 Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| 04/30/1998 | WO1998017678A1 Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides |
| 04/30/1998 | WO1998017667A1 6',7'-dihydroxybergamottin, a cytochrome p450 ihnibitor in grapefruit juice |
| 04/30/1998 | WO1998017643A1 Heteroaryl succinamides and their use as metalloproteinase inhibitors |
| 04/30/1998 | WO1998017321A1 Gene delivery and expression in areas inaccessible to direct protein delivery |
| 04/30/1998 | WO1998017320A1 Use of hyaluronan in gene therapy |
| 04/30/1998 | WO1998017319A2 Platelet substitutes and conjugation methods suitable for their preparation |
| 04/30/1998 | WO1998017314A1 Use of macrophage migration inhibitory factor antagonists for anti-cancer therapy |
| 04/30/1998 | WO1998017313A2 Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases |
| 04/30/1998 | WO1998017308A1 Inhibiting hiv infection by cleaving co-receptor rna |
| 04/30/1998 | WO1998017307A1 Method and composition for treating neuronal degeneration |
| 04/30/1998 | WO1998017305A1 USE OF FasL OR FasL TRANSFECTED CD4+/FasL-/TH1-CELL LINES FOR THE TREATMENT OF TH1/TH2 DISEASES |
| 04/30/1998 | WO1998017304A1 Anti-fibrotic agent assay |
| 04/30/1998 | WO1998017303A1 A method for the treatment of streptococcus pneumoniae infection |
| 04/30/1998 | WO1998017302A1 Total synthesis of the amino hip analogue of didemnin a |
| 04/30/1998 | WO1998017301A1 Peptides for inhibiting retroviruses |
| 04/30/1998 | WO1998017300A1 Mucin-mediated immunomodulation |
| 04/30/1998 | WO1998017299A1 Isozyme-specific activators of protein kinase c, methods and compositions |
| 04/30/1998 | WO1998017289A1 Therapeutic use of hemoglobin to treat head injury |
| 04/30/1998 | WO1998017284A2 Inhibition of cap-independent protein synthesis and hiv-tar translation by heparin or heparin mimetics, and methods for gene therapy |
| 04/30/1998 | WO1998017275A1 Semi-synthetic studies toward didemnin analogues |
| 04/30/1998 | WO1998017274A1 Thrombin inhibitors |
| 04/30/1998 | WO1998017272A1 Use of antibodies to sialidase as anti-infectious agents and anti-inflammatory agents |
| 04/30/1998 | WO1998017246A1 Use of complexes for the preparation of compositions for the treatment of sensitive skin, preparation process and hypoallergenic compositions |
| 04/30/1998 | WO1998017242A1 Unique peptides for targeting fibronectin-enriched surfaces and a method for their delivery in the treatment of metastatic cancer |
| 04/30/1998 | WO1998017116A1 Targeted cytotoxic cells |
| 04/30/1998 | WO1998012213A3 Cysteine containing peptides |
| 04/30/1998 | WO1998011225A3 A novel haemopoietin receptor and genetic sequences encoding same |
| 04/30/1998 | WO1998005685A3 Self-aligning peptides derived from elastin and other fibrous proteins |
| 04/30/1998 | WO1998004694A3 Secreted proteins and polynucleotides encoding them |
| 04/30/1998 | WO1997048795A3 Compositions and methods for treating specific gene expression-related diseases and disorders in humans |
| 04/30/1998 | DE19644501A1 GABA¶A¶-Rezeptoruntereinheit epsilon-verwandtes Protein GABA¶A¶ receptor epsilon subunit-related protein |
| 04/30/1998 | CA2751712A1 Immunotherapy and improved vaccines |
| 04/30/1998 | CA2745736A1 Immunotherapy and improved vaccines |
| 04/30/1998 | CA2272601A1 Peptides for inhibiting retroviruses |
| 04/30/1998 | CA2271721A1 Mini-e1a genes and gene products |
| 04/30/1998 | CA2270154A1 Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian cd97 alpha subunit |
| 04/30/1998 | CA2269881A1 Semi-synthetic studies toward didemnin analogues |
| 04/30/1998 | CA2269878A1 Total synthesis of the amino hip analogue of didemnin a |
| 04/30/1998 | CA2269825A1 Gene delivery and expression in areas inaccessible to direct protein delivery |
| 04/30/1998 | CA2269755A1 Secreted proteins and polynucleotides encoding them |
| 04/30/1998 | CA2269711A1 Anti-fibrotic agent assay |
| 04/30/1998 | CA2269656A1 Receptor specific brain natriuretic peptide (bnp) |
| 04/30/1998 | CA2269644A1 Inhibiting hiv infection by cleaving co-receptor rna |
| 04/30/1998 | CA2269614A1 Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases |
| 04/30/1998 | CA2269533A1 Use of antibodies to sialidase as anti-infectious agents and anti-inflammatory agents |
| 04/30/1998 | CA2269507A1 Targeted cytotoxic cells |
| 04/30/1998 | CA2269349A1 Mucin-mediated immunomodulation |
| 04/30/1998 | CA2269121A1 Production of cartilage tissue using cells isolated from wharton's jelly |
| 04/30/1998 | CA2269100A1 Methods and compositions for delivery and expression of interferon-.alpha. nucleic acids |
| 04/30/1998 | CA2269074A1 Immunotherapy and improved vaccines |
| 04/30/1998 | CA2269034A1 Use of fasl or fasl transfected cd4+/fasl-/th1-cell lines for the treatment of th1/th2 diseases |
| 04/30/1998 | CA2269025A1 Pancreatic lipases and/or recombinant colipases and derived polypeptides produced by plants, methods for obtaining them and use thereof |
| 04/30/1998 | CA2268949A1 Mitochondrial dna mutations that segregate with late onset diabetes mellitus |
| 04/30/1998 | CA2268751A1 Fringe proteins and notch signalling |
| 04/30/1998 | CA2268746A1 Placental-derived prostate growth factors |
| 04/30/1998 | CA2268744A1 Novel lanthionine antibiotic compositions and methods |
| 04/30/1998 | CA2268742A1 Multi-functional chimeric hematopoietic receptor agonists |
| 04/30/1998 | CA2268517A1 Therapeutic use of hemoglobin to treat head injury |
| 04/30/1998 | CA2268476A1 Use of hyaluronan in gene therapy |
| 04/30/1998 | CA2268391A1 Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| 04/30/1998 | CA2268365A1 Il-12 gene expression and delivery systems and uses |
| 04/30/1998 | CA2268278A1 Methods of reducing the levels of protoporphyrin ix in recombinant hemoglobin preparations |
| 04/30/1998 | CA2268045A1 Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use |
| 04/30/1998 | CA2268016A1 Human eosinophil-derived basic protein |
| 04/30/1998 | CA2267260A1 Thrombin inhibitors |
| 04/30/1998 | CA2264794A1 A method for the treatment of streptococcus pneumoniae infection |
| 04/30/1998 | CA2263732A1 Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides |
| 04/29/1998 | EP0838525A2 Streptococcus pneumoniae polypeptide greA |
| 04/29/1998 | EP0838524A2 RsbV-1 derived from Staphylococcus |
| 04/29/1998 | EP0838523A2 RsbW-1 derived from Staphylococcus |
| 04/29/1998 | EP0838474A1 Peptide that inhibits blood triglyceride level rise and blood triglyceride level rise inhibitor containing said peptide as active ingredient |
| 04/29/1998 | EP0838473A1 Peptide for inhibiting blood triglyceride level rise and inhibitor for blood triglyceride level rise comprising the peptide as active ingredient |
| 04/29/1998 | EP0838472A1 Peptides binding to low-density lipoproteins |
| 04/29/1998 | EP0838471A1 Peptide derivatives and angiotensin iv receptor agonist |
| 04/29/1998 | EP0838223A1 Brain edema inhibitor |
| 04/29/1998 | EP0838221A1 Lyophilized hgf preparations |
| 04/29/1998 | EP0838213A1 Use of Krill Enzymes for the Treatment of Dental Plaque |
| 04/29/1998 | EP0837951A1 Antisense inhibition of hepatitis b virus replication |
| 04/29/1998 | EP0837939A2 Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods |
| 04/29/1998 | EP0837938A2 Use of mp52 or mp121 for treating and preventing diseases of the nervous system |
| 04/29/1998 | EP0837936A1 New immunoregulatory protein lst-1 |
| 04/29/1998 | EP0837934A1 Human vascular endothelial growth factor 2 |
| 04/29/1998 | EP0837933A1 Optimized minizymes and miniribozymes and uses thereof |
| 04/29/1998 | EP0837932A1 Macrophage activating factors derived from cloned vitamin d binding protein |
| 04/29/1998 | EP0837930A1 HUMAN GLANDULAR KALLIKREIN-1 (hK2) |
| 04/29/1998 | EP0837927A1 Monkey monoclonal antibodies specific to human b7.1 and/or b7.2 primatized forms, pharmaceutical compositions |